Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Publication of ECSP034863ApublicationCriticalpatent/ECSP034863A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una combinación de un agonista selectivo del receptor A2a de adenosina y un agente anticolinérgico para la administración simultánea, consecutiva o separada por vía de inhalación en el tratamiento de una enfermedad obstructiva de las vías aéreas u otra enfermedad inflamatoria, con la condición de que el agente anticolinérgico no sea una sal tiotropioThe present invention relates to a combination of a selective adenosine A2a receptor agonist and an anticholinergic agent for simultaneous, consecutive or separate administration by inhalation in the treatment of an obstructive airway disease or other inflammatory disease, with the condition that the anticholinergic agent is not a tiotropium salt
ECSP0348632001-05-252003-11-25
AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES
ECSP034863A
(en)
Restless Leg Syndrome Treatment Method, Adenoin a2a Receptor Antagonist Use, Therapeutic Agent for Restless Leg Syndrome, and Night Myoclonus Treatment Method